Product/Composition:- | Vildagliptin Tablets |
---|---|
Strength:- | 50 mg |
Form:- | Tablets |
Reference Brands:- | Galvus (EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Vildagliptin inhibits the enzyme DPP-4, which prolongs the activity of incretin hormones like GLP-1 and GIP. This enhances insulin secretion and suppresses glucagon release in a glucose-dependent manner, improving glycemic control without causing hypoglycemia. It is well-tolerated and weight-neutral, making it ideal for type 2 diabetes management.
Vildagliptin is a DPP-4 inhibitor used to manage type 2 diabetes mellitus by enhancing incretin levels, improving insulin secretion, and reducing glucagon production. While not FDA-approved in the USA, it holds EMA approval and is widely marketed in the EU under brand names like Galvus and Galvus Met. Vildagliptin is available as monotherapy or in fixed-dose combinations with metformin. EU regulatory bodies emphasize its safety, tolerability, and cardiovascular neutrality. Pharmatradz.com connects global buyers and suppliers to EU-approved vildagliptin formulations, enabling seamless B2B transactions in the regulated pharmaceutical market.